PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22212931-4	2011	Molecular therapies such as sorafenib, a BRAF/ VEGFR/PDGFR tyrosine kinase inhibitor, have shown to improve survival in patients with advanced HCC.	Sorafenib	28-37	B-Raf proto-oncogene, serine/threonine kinase	Homo sapiens	41-45